Find research datasets worth reusing

The Impact of Culture in Cognitive Behavior Therapy (CBT) for Patients With Inflammatory Bowel Disease

ClinicalTrials.gov study NCT06713694. IPD Sharing: Not stated. Countries: 1. Publications: 0.

Care Coordination and Proactive Care to Improve Utilization of Resources and Reduce Expenditure in High Risk Inflammatory Bowel Disease (IBD) Patients

ClinicalTrials.gov study NCT04796571. IPD Sharing: NO. Countries: 1. Publications: 1.

Self-care in Patients Affected by Inflammatory Bowel Disease and Caregivers' Contribution to Self-care

ClinicalTrials.gov study NCT06015789. IPD Sharing: Not stated. Countries: 1. Publications: 2.

Immunogenicity of Hepatitis A Vaccine in Inflammatory Bowel Disease (IBD) Patients

ClinicalTrials.gov study NCT01341808. IPD Sharing: Not stated. Countries: 1. Publications: 3.

Risk Factors for Colorectal Cancer in Patients With Inflammatory Bowel Disease Undergoing Surveillance: a Prospective Cohort Study

ClinicalTrials.gov study NCT01464151. IPD Sharing: Not stated. Countries: 1. Publications: 1.

Biological Therapy in Patients With Inflammatory Bowel Disease

ClinicalTrials.gov study NCT05599867. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.

publicJun 2024View details →

dryad32/100

Biohybrid microrobots regulate colonic cytokine and epithelium barrier in inflammatory bowel disease

Open the record for dataset details and reuse information.

dryad28/100

Data from: Humoral immune responses against gut bacteria In dogs with inflammatory bowel disease

Inflammatory bowel disease (IBD) in dogs is associated with clinical signs of intestinal dysfunction, as well as abnormal lymphocytic and myeloid cell infiltrates in the small and/or large intestine. Thus, in many respects IBD in dogs resembles IBD in humans. However, the factors that trigger intestinal inflammation in dogs with IBD are not well understood and have been variously attributed to immune responses against dietary antigens or intestinal antigens. Previous studies in humans with IBD have documented increased production of IgG and IgA antibodies specific to intestinal bacteria, and this abnormal immune response has been linked to disease pathogenesis. Therefore, we investigated the humoral immune response against gut bacteria in dogs with IBD, using flow cytometry to quantitate IgG and IgA binding. Studies were also done to investigate the source of these antibodies (locally produced versus systemic production) and whether greater antibody binding to bacteria is associated with increased inflammatory responses. We found that dogs with IBD had significantly higher percentages and overall amounts of IgG bound to their intestinal bacteria compared to healthy dogs. Similarly, significantly higher percentages of bacteria were IgA+ bacteria were also found in dogs with IBD. Serum antibody recognition of gut bacteria was not different between healthy dogs and dogs with IBD, suggesting that anti-bacterial antibodies were primarily produced locally in the gut rather than systemically. Importantly, bacteria in the Actinobacteria phylum and in particular the genus Collinsella had significantly greater levels of antibody binding in dogs with IBD. Based on these findings, we concluded that antibody binding to commensal gut bacteria was significantly increased in dogs with IBD, that particular phyla were preferential targets for gut antibodies, and that anti-bacterial antibody responses may play an important role in regulating gut inflammation.

opencc-zeroAug 2019View details →

dryad28/100

Data from: An objective in vivo diagnostic method for inflammatory bowel disease

Inflammatory damage to the bowel, as occurs in inflammatory bowel disease (IBD), is debilitating to patients. In both patients and animal experimental models histological analysis of biopsies and endoscopic examinations are used to evaluate the disease state. However such measurements often have delays and are invasive, while endoscopy is not quantitatively objective. Therefore, a real-time quantitative method to assess compromised mucosal barrier function is advantageous. We investigated the correlation of in vivo changes in electrical transmural impedance with histological measures of inflammation. Four platinum (Pt) ball electrodes were placed in the lumen of the rat small intestine, with a return electrode under the skin. Electrodes placed within the non-inflamed intestine generated stable impedances during the 3 h testing period. Following intraluminal injection of 2,4,6-trinitrobenzene sulphonic acid (TNBS), an established animal model of IBD, impedances in the inflamed region significantly decreased relative to a region not exposed to TNBS (P < 0.05). Changes in intestinal transmural impedance were correlated (P < 0.05) with histologically assessed damage to the mucosa and increases in neutrophil, eosinophil and T-cell populations at 3 h compared with tissue from control regions. This quantitative, real-time assay may have application in the diagnosis and clinical management of IBD.

opencc-zeroDec 2017View details →

zenodo28/100

scRNA-seq data for "Bacteroides fragilis toxin suppresses METTL3-Mediated m6A modification in macrophage to promote inflammatory bowel disease"

Open the record for dataset details and reuse information.

opencc-by-4.0Apr 2024View details →

Evolution of Fatigue in Patients With Inflammatory Bowel Disease

ClinicalTrials.gov study NCT04189692. IPD Sharing: NO. Countries: 0. Publications: 2.

Comparing the Accuracy of Different Ultrasound-based Scores to Assess Disease Severity in Patients with Inflammatory Bowel Disease

ClinicalTrials.gov study NCT06705972. IPD Sharing: NO. Countries: 0. Publications: 5.

Study of the Relationship Between Glycogen Storage Disease Type Ia and Inflammatory Bowel Disease

ClinicalTrials.gov study NCT01854242. IPD Sharing: Not stated. Countries: 1. Publications: 0.

Assessment of Nutritional Knowledge in Patients With Inflammatory Bowel Disease

ClinicalTrials.gov study NCT04882566. IPD Sharing: NO. Countries: 0. Publications: 3.

The Effect of Joint Transition Visits on Quality of Life in Inflammatory Bowel Diseases (TRANS-IBD)

ClinicalTrials.gov study NCT04290156. IPD Sharing: NO. Countries: 0. Publications: 7.

Diagnosis of Inflammatory Bowel Disease

ClinicalTrials.gov study NCT07400211. IPD Sharing: UNDECIDED. Countries: 0. Publications: 16.

Manitoba Inflammatory Bowel Disease Cohort Study

ClinicalTrials.gov study NCT03262649. IPD Sharing: NO. Countries: 0. Publications: 60.

Efficacy and Safety of Discontinuing 5-ASA in Patients With Inflammatory Bowel Disease

ClinicalTrials.gov study NCT06878495. IPD Sharing: NO. Countries: 0. Publications: 6.

Renal Involvement in Adult Patients with Inflammatory Bowel Disease and Its Relation to Duration and Disease Activity

ClinicalTrials.gov study NCT06717516. IPD Sharing: UNDECIDED. Countries: 0. Publications: 6.

Endoscopically Placed Lumen-Apposing Metal Stents for the Treatment of Symptomatic Intestinal Strictures in Individuals With Inflammatory Bowel Disease

ClinicalTrials.gov study NCT06725563. IPD Sharing: NO. Countries: 0. Publications: 16.